Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa (Virtual)
Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa
The goal of this clinical trial is to evaluate whether a narrative medicine (NM) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa.
The main questions it aims to answer are:
- Does participation in an NM curriculum improve self-expression and reflection in individuals with anorexia nervosa?
- Does engaging in creative writing and group discussion promote resilience and emotional processing in this population?
Participants will be 16-25 years old, medically stable for outpatient eating disorder therapy, and actively engaged in treatment. Those with active suicidal ideation, recent non-suicidal self-injury, or a co-occurring personality disorder will not be eligible.
Participants will:
- Attend six weekly workshops focused on themes such as self-definition, kindness, resilience, and possibility
- Engage in close reading of visual or written texts
- Complete creative writing exercises in response to prompts
- Participate in group discussions and sharing
An optional capstone reading event will provide a supportive space for participants to share their work with peers, loved ones, and providers, fostering connection and community.
This study aims to explore the role of narrative medicine in eating disorder treatment and assess its potential benefits for psychological well-being and self-expression.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Anoushka A Sinha, MD, MS
- Número de teléfono: 628-286-6116
- Correo electrónico: anoushka.sinha@ucsf.edu
Ubicaciones de estudio
-
-
California
-
San Francisco, California, Estados Unidos, 94158
- Reclutamiento
- UCSF Nancy Friend Pritzker Psychiatry Building
-
Contacto:
- Sara Buckelew, MD, MPH
- Número de teléfono: 415-502-1649
- Correo electrónico: sara.buckelew@ucsf.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 16-25 years old
- have a DSM-5 diagnosis of AN (confirmed by the UCSF Eating Disorders Program clinical team),
- currently engaged in outpatient eating disorder treatment, ensuring medical stability and capacity for a group-based intervention
- English fluency to engage in reflective writing and discussions
- Cognitive ability to meaningfully participate in narrative-based exercises
Exclusion Criteria:
- Currently medically unstable or require inpatient hospitalization
- History of psychosis, schizophrenia spectrum disorder, bipolar disorder, or personality disorder
- Severe neurocognitive impairment that would prevent engagement with the intervention
- Active suicidal ideation or non-suicidal self-injury within the past two months
- Insufficient English proficiency to participate in group discussions and writing exercises
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Narrative Medicine (NM) Workshop Series
Participants in this study will take part in a six-week Narrative Medicine (NM) curriculum designed to enhance self-expression, reflection, and resilience in individuals with anorexia nervosa. Workshops will be conducted weekly on Zoom and will include:
|
The Narrative Medicine (NM) Workshop Series is a structured six-week behavioral intervention designed to enhance self-expression, reflection, and resilience in adolescents and young adults recovering from eating disorders. This intervention differs from traditional psychotherapeutic or psychoeducational approaches by integrating literary analysis, creative writing, and guided discussion as therapeutic tools. Each one-hour weekly workshop includes:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants in each session
Periodo de tiempo: Immediately post-intervention (Week 6)
|
Feasibility will be measured by participant retention in intervention. |
Immediately post-intervention (Week 6)
|
|
Satisfaction with intervention components using 5-point Likert scales and semi-structured individual interviews
Periodo de tiempo: Immediately post-intervention (Week 6)
|
Acceptability will be measured by questionnaire including 5-point Likert scales and semi-structured individual interviews assessing content relevance, writing prompts, group discussions, and facilitation. Scale title: Intervention Satisfaction Questionnaire (ISQ) Minimum value: 1 (Strongly Disagree) Maximum value: 5 (Strongly Agree) Interpretation: Higher scores indicate greater satisfaction with the intervention (better outcome). |
Immediately post-intervention (Week 6)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Illness-Identity Centrality
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)
|
Assessed using the Illness Identity Questionnaire, which evaluates self-concept clarity and personal identity coherence. Scale title: Illness Identity Questionnaire (IIQ) Minimum value: 1 (Strongly Disagree) Maximum value: 5 (Strongly Agree) Interpretation: Subscale scores reflect distinct illness identity states; higher scores indicate greater endorsement of that identity orientation |
Pre- (Week 0) and immediately post-intervention (Week 6)
|
|
Social Connectedness
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)
|
Measured using the Social Connectedness Scale (SCS), which assesses perceived closeness to others and sense of belonging. Scale title: Social Connectedness Scale (SCS) Minimum value: 1 (Strongly Disagree) Maximum value: 6 (Strongly Agree) Interpretation: Higher scores indicate greater feelings of social connectedness and belonging (better outcome). |
Pre- (Week 0) and immediately post-intervention (Week 6)
|
|
Depression Symptoms
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)
|
Measured using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms. Scale title: Patient Health Questionnaire-9 (PHQ-9) Minimum value: 0 (Not at all) Maximum value: 3 (Nearly every day) Interpretation: Higher scores indicate greater severity of depressive symptoms (worse outcome). |
Pre- (Week 0) and immediately post-intervention (Week 6)
|
|
Anxiety Symptoms
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)
|
Measured using the Generalized Anxiety Disorder-7 (GAD-7) for anxiety. Scale title: Generalized Anxiety Disorder 7-item (GAD-7) Scale Minimum value: 0 (Not at all) Maximum value: 3 (Nearly every day) Interpretation: Higher scores indicate greater severity of anxiety symptoms (worse outcome). |
Pre- (Week 0) and immediately post-intervention (Week 6)
|
|
Eating Disorder Severity
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)
|
Measured using the Eating Disorder Examination Questionnaire (EDE-Q), which captures cognitive and behavioral symptoms of AN, and percent of expected body weight (EBW) at follow-up. Scale title: Eating Disorder Examination Questionnaire (EDE-Q) Minimum value: 0 (No days / Not at all) Maximum value: 6 (Every day / Extremely) Interpretation: Higher scores indicate greater severity of eating disorder psychopathology (worse outcome). |
Pre- (Week 0) and immediately post-intervention (Week 6)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Anoushka Sinha, MD, MS, University of California, San Francisco
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 24-43017 (b)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .